- Global Pharma News & Resources

US and EU CBD Dietary Supplement Regulatory Report 2021 -

DUBLIN--(BUSINESS WIRE)--The "Regulatory Report: CBD as a Dietary Supplement in the US and EU" report has been added to's offering.

In Europe, regulatory authority is divided between the EU and individual member states. The EU defines CBD as a novel food, requiring express authorisation.

In the US, its approval by the FDA in a pharmaceutical product precludes its use as a food or dietary supplement - though that has been subject to court involvement.

As CBD grows in popularity, its regulatory status remains poorly defined. In this report the publisher reviews the regulatory framework of dietary supplements and where CBD fits, or would fit, within that framework.

Both the US and the EU have regulatory standards governing the marketing of food supplements. Most of the US Food and Drug Administration (FDA)'s powers appear to be aimed at regulating what can be said about a substance rather than scrutinising them before they are marketed. Claims may be either health claims related to a particular condition, or general structure/function claims.

Key Topics Covered:

1 Executive summary

2 Introduction

3 United States

4 Europe

5 Current status of CBD as a dietary supplement

6 Case study: melatonin - a comparison of evidence

7 Conclusion

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 16-Jul-2021